)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
electroCore
electroCore (ECOR) investor relations material
electroCore Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 net sales reached a record $9.690M, up 12% YoY; GAAP net loss narrowed to $1.339M and adjusted EBITDA loss to $0.680M.
Management expects accelerating growth and a first positive adjusted EBITDA quarter by end-2027, while forecast liquidity needs raise substantial doubt about funding planned operations for at least 12 months.
Financial highlights
Q3 gross profit increased to $8.573M from $7.470M; operating expenses declined to $10.129M from $10.354M.
Q3 operating loss was $1.556M versus $2.884M; net loss per share was $0.13 versus $0.40.
Q3 adjusted EBITDA loss was $0.680M versus $2.043M; nine-month adjusted EBITDA loss was $4.758M versus $7.479M.
Nine-month net sales rose 26% to $28.724M; net loss was $9.7M versus $10.9M, and operating cash use increased to $9.4M from $6.6M.
Q3 SG&A was $9.698M, essentially flat YoY; R&D declined to $0.431M from $0.662M.
Outlook and guidance
FY2026 revenue guidance was revised to $39M–$42M from prior guidance of greater than 30% growth; most revenue is expected to continue coming from VA prescription sales.
Preliminary FY2027 revenue growth guidance is 30%–40%, with a first positive adjusted EBITDA quarter expected by end-2027.
Outlook assumes VA sales-force expansion, smaller-territory accountability, operating leverage and potential Quell CIPN label expansion subject to FDA clearance.
Expected second-half 2026 acceleration shifted into 2027 as sales-force changes take longer to achieve full coverage; refill-rate improvement is expected from Q4 2026 into early 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from electroCore
- H1 revenue grew 35%, with FY26 growth guidance raised above 30%.ECOR
Corporate presentation - Federal-market expansion and Quell’s pipeline support a 2H2027 adjusted EBITDA target.ECORPlanet MicroCap Showcase: Toronto 2026
- Directors were elected, auditors ratified, and executive pay approved; no shareholder proposals.ECORAGM 2026
- Bioelectronic medicine firm posts strong revenue growth and expands FDA-cleared product reach.ECORCorporate presentation
- Q2 2026 sales up 28%, net loss narrows, but cash burn raises going concern risks.ECORQ2 2026
- Board recommends voting for directors, auditor ratification, and executive pay at the 2026 virtual meeting.ECORProxy filing
- Q3 revenue up 45% year-over-year, net loss narrows, and cash position strengthens.ECORQ3 2024
- Q2 sales hit $6.1M, margin rose to 86%, and $9M was raised, led by VA/DoD and Truvaga growth.ECORQ2 2024
- Q1 2025 revenue up 23% to $6.7M; NeuroMetrix acquired; gross margin 85%; $30M FY outlook.ECORQ1 2025
Next electroCore earnings date
Q4 202617 Mar, 2027
electroCore
Next electroCore earnings date
Q4 202617 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
electroCore Inc is a commercial-stage medical technology company that develops and markets non-invasive neuromodulation devices. Its primary product, a handheld device, uses electrical stimulation to target the vagus nerve for the treatment of various conditions, including migraines and cluster headaches. The company’s technology is designed to offer patients a non-drug, non-invasive alternative for pain management and neurological disorders. electroCore is also exploring the potential use of its platform in other therapeutic areas such as respiratory diseases and inflammatory conditions. The company is headquartered in Rockaway, New Jersey, and its shares are listed on the NASDAQ.